Subscribe To
Monthly realty income is about to get bigger
Higher interest rates may make it more difficult for a vast population to fulfill their dreams of ownin...
March 9, 2023, 9:22 am
Bionomics reports promising full results analysis from prevail phase 2 study of bnc210 social anxiety disorder (sad)
Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challenge Results achieved ...
March 9, 2023, 12:00 am
Activists rally, some governments seek change as world marks women’s day
(Reuters) – Activists planned rallies and marches to celebrate International Women’s Day on Wednesday while governments in several countries promi...
March 8, 2023, 6:36 am
Fintech in emerging markets: opportunities and challenges for growth
Fintech has been disrupting the financial services industry all over the world, but it has had an especially large impact in emerging markets. In t...
March 7, 2023, 5:38 pm
Turkey receives $5 billion lifeline but lira still drops
It has been a very difficult time for Turkey and its hard-working population over the past five years.B...
March 7, 2023, 12:07 pm
Immuneering presents preclinical data with lead program imm-1-104 supporting universal-ras activity
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-...
March 5, 2023, 11:30 pm
Amarin announces new reduce-it® data at acc.23/wcc showing benefit of vascepa®/vazkepa® (icosapent ethyl) in high-risk patients with a recent acute coronary syndrome event
–Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS With...
March 5, 2023, 3:21 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Four “unwinnable” personal injury cases that defied the odds
With One-Third of Americans Skeptical of the Legal System, Attorney Mitchel Ashley Restores Faith By Persistently Challenging the “Rules of the Game...
March 3, 2023, 7:04 am
New clinical studies demonstrate that sword health improves outcomes and advances health equity for underserved patients with muscle and joint pain
The studies are the first to evaluate how underserved patient populations progress when given access to...
March 2, 2023, 7:35 pm
Free education, equal rights for unmarried women among proposals to boost china’s fertility
By Farah Master HONG KONG (Reuters) – Free college education and equal rights for unmarried women are among proposals being urged by members of Chin...
March 2, 2023, 6:51 am
3 ai stocks that are revolutionizing agriculture
There is a lot of buzz surrounding investing in agriculture AI stocks. Companies turn to AI technology for solutions as the world ...
March 1, 2023, 1:17 pm
Anti-embolism stockings market is likely to accelerate at a steady cagr of 5.2% and reach a us$ 1.2 billion by 2032 | persistence market research
Rising Prevalence of Venous Disorders and Increasing Geriatric population Driving Need for Anti-Embolis...
March 1, 2023, 12:00 pm
How to supercharge your portfolio with apollo and other alt managers
High-growing and sizable alt management industry is not represented in the S&P 500 index today. Adding individual alt managers to diversified portfoli...
February 28, 2023, 4:47 am
Featuring mapuche heroine, chilean amazon original action film ‘sayen' premieres on prime video
The film is the first in a Chilean original action trilogy in which the title character seeks justice and defends indigenous ...
February 27, 2023, 8:14 pm
